Evidence map›Paper›PMID 42546045›Full record

ArticlePLoS pathogens2026

Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.

Ling Zhou, Ching-Lin Hsieh, Sarah R Leist, Emily Happy Miller, Andrew P Horton, Sophie R Shoemaker, Elizabeth C Gardner, John M Powers, Daniel R Boutz, Michael L Mallory and 12 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ling ZhouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Ching-Lin HsiehDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Emily Happy MillerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Andrew P HortonDepartment of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute, Houston, Texas, United States of America.
Sophie R ShoemakerDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, United States of America.
Elizabeth C GardnerDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
John M PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Daniel R BoutzDepartment of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute, Houston, Texas, United States of America.
Michael L MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Connor M MullinsDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Nicole V JohnsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Alexandra L TseDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Albert WangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Kamyab JavanmardiDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Lily E AdamsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jonathan SchislerMcAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Susan MarquseeDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, United States of America.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jimmy D GolliharDepartment of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute, Houston, Texas, United States of America.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.ORCID 0000-0003-3991-542X

Funding

Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI Neil King, David Veesler · 2022 to 2026
$15.3M
CTSA K12 Program at Einstein-MontefioreK12TR004411 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Deepa Rastogi · 2023 to 2026
$3.0M
Sequence and Environmental Determinants of the Protein Energy LandscapeR35GM149319 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI SUSAN MARQUSEE · 2023 to 2026
$1.7M
Bill & Melinda Gates Foundation INV-031624NCATS NIH HHS K12 TR004411NIAID NIH HHS P01 AI167966NIGMS NIH HHS R35 GM149319
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone extensive evolution since its emergence in 2019, underscoring the continuous need for vaccines and therapeutics effective against multiple variants of concern (VOCs). The S2 subunit of the viral spike (S) glycoprotein is highly conserved among sarbecoviruses, making it an attractive target for broadly protective countermeasures. To elucidate the S2 antigenic landscape, we employed yeast surface display to isolate S2-targeted antibodies from COVID-19 convalescent donors. Biophysical characterization revealed that these S2 apex-directed antibodies preferentially bind to open spike conformations and a stabilized S2 construct but not to the closed, trimeric prefusion spike. Cryo-electron microscopy structures defined a cryptic epitope encompassing the upper helix and fusion peptide proximal region on S2. This epitope is conserved among sarbecoviruses but remains largely occluded in the closed prefusion conformation of the spikes. As a result, the antibodies exhibited weak neutralization activity against SARS-CoV-2 pseudoviruses, failed to neutralize authentic viruses, and did not provide protection in a lethal mouse challenge model using a mouse-adapted SARS-CoV-2 strain. These findings highlight a non-neutralizing epitope on S2 capable of eliciting antibodies during SARS-CoV-2 infection in humans and provide valuable reagents for probing S2 conformational dynamics and optimizing S2-based vaccine antigens.

Indexed as

COVID-19EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralCryoelectron MicroscopyHumansMiceAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID42546045
PMCPMC13432147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.